WO2005018629A1 - Treatment for acne vulgaris and method of use - Google Patents

Treatment for acne vulgaris and method of use Download PDF

Info

Publication number
WO2005018629A1
WO2005018629A1 PCT/US2003/025207 US0325207W WO2005018629A1 WO 2005018629 A1 WO2005018629 A1 WO 2005018629A1 US 0325207 W US0325207 W US 0325207W WO 2005018629 A1 WO2005018629 A1 WO 2005018629A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
acne vulgaris
ethoxylate
composition
exchanged
Prior art date
Application number
PCT/US2003/025207
Other languages
French (fr)
Inventor
William M. Yarbrough
Original Assignee
Yarbrough William M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yarbrough William M filed Critical Yarbrough William M
Priority to AU2003264053A priority Critical patent/AU2003264053A1/en
Priority to JP2005508238A priority patent/JP2007521234A/en
Priority to PCT/US2003/025207 priority patent/WO2005018629A1/en
Priority to EP03818329A priority patent/EP1656128A4/en
Priority to CA002535550A priority patent/CA2535550A1/en
Publication of WO2005018629A1 publication Critical patent/WO2005018629A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a composition including surfactants for the treatment of acne vulgaris. Methods of use are also included ⁇ . BACKGROUND OF THE INVENTION AND PRIOR ART Acne vulgaris (or "acne") is a disorder of the sebaceous glands. It is characterized by lesions that are either non-inflammatory or inflammatory papules and nodules. Non-inflammatory papules may be open, commonly referred to as “blackheads", or closed, commonly referred to as “whiteheads”. As a group, non- inflammatory papules are called comedones.
  • a topical treatment for acne 5 vulgaris a topical treatment for acne 5 vulgaris.
  • a method is provided for applying a composition of 6 substances to the infected area, working the composition into the infected area, and 7 removing the composition from the infected area.
  • the composition comprises at least 8 one ethoxylate in combination with Sodium Lauroyl Sarcosinate (or "SLS").
  • SLS Sodium Lauroyl Sarcosinate
  • An inert 9 scrubbing agent such as polyethylene beads, can also be included to the formula.
  • Acetylated lanolin alcohol, a second ethoxylate, EDTA, a foam stabilizer, and water can 11 also be added to the composition without effecting performance.
  • Other formulas that keep the polarity similar to that of the inventive formula will 13 also work. To keep the polarity similar, it is necessary for the compound to have similar 14 characteristics, such as Carbon chains, carbonyl groups, Nitrogen bound to Carbon, 15 Aromatic ring(s), Oxylate groups, and appropriate functional groups at the ends of the 16 individual molecules.
  • the ideal substitute chemicals would have all of the characteristics 17 mentioned above, but it is not necessary to have every one of those as listed.
  • the cutting agent must be added only in 2 sufficient amount that it promotes flow but does not effect the action of the composition. 3
  • an sufficient amount of the composition is used to cover the infected area, 4 the composition is applied to an infected area and worked over the area by a scrubbing 5 motion. After sufficient time has elapsed to ensure that the infected area has been 6 adequately exposed to the composition such that they area feels clean, approximately ten 7 to thirty seconds for the typical person, the area is rinsed cleaned.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A treatment for Acne Vulgaris is provided for in a topical treatment. According to the invention, a method is provided for applying composition substances to the infected area, working the composition into the infected area, and removing the composition from the infected area. The composition comprises at least one ethoxylate in combination with Sodium Lauroyl Sarcosinate. Alternatively, the ethoxylate can be exchanged for a methoxylate or a propoxylate. An inert scrubbing agent, such as polyethylene beads, can also be included. Acetylated lanolin alcohol, sodium Lauroyl Sarcosinate, EDTA, a foam stabilizer, and water can also be added to the composition to assist performance.

Description

Invention: Treatment for Acne Vulgaris and Method of Use Inventor: William M. Yarbrough I. FIELD OF THE INVENTION The present invention relates to a composition including surfactants for the treatment of acne vulgaris. Methods of use are also included π. BACKGROUND OF THE INVENTION AND PRIOR ART Acne vulgaris (or "acne") is a disorder of the sebaceous glands. It is characterized by lesions that are either non-inflammatory or inflammatory papules and nodules. Non-inflammatory papules may be open, commonly referred to as "blackheads", or closed, commonly referred to as "whiteheads". As a group, non- inflammatory papules are called comedones. Closed comedones can lead to inflammatory nodules, papules, and pustules. Severe cases of acne vulgaris can lead to scars characterized by pitting. It is believed that acne results from partial rupture of a partially inflamed follicle. The follicle then spills its components, thereby resulting in the development of a perifollicular inflammatory process. Generally, fresh lesions are sterile, but later gram- positive diptheroids are present. Many times the skin will have a greasy look to it; this is probably due, at least in part, to the release of fatty acids during lipolysis induced by P. acnes. Acne can be a serious problem. It generally manifests itself during adolescence and spontaneously resolves in the late teens or early twenties; although for some, it can be a life long problem. Mild to moderate acne is most often treated with topical agents. INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 More severe cases are treated with incision and drainage of lesions, ultraviolet light 2 therapy, and systemic antibiotics. 3 The prior art is replete with compositions for use in the treatment of acne. 4 Topical agents, such as benzoyl peroxide, are thought to decrease bacteria and are often 5 used in the treatment of acne. These treatments are found in many forms, lotions, gels, 6 pads, etc. and are generally available over the counter. Retinol in various forms has been 7 more recently proposed by various Inventors. There are also many soaps used in the 8 treatment of acne. A major shortcoming of most of the prior art is that they often do not 9 penetrate sufficiently and they leave the skin dry. 10 H. OBJECTS OF THE INVENTION 11 It is an object of the present invention to provide a treatment that helps to alleviate 12 the local signs and symptoms caused by acne vulgaris. 13 It is a further object of the present invention to provide a method of use of the 14 present inventive treatment. 15 It is yet another object of the present invention to provide a treatment that 16 includes at least a first nonyl phenyl ethoxylate and sodium lauroyl sarcosinate to which a 17 second nonyl phenyl ethoxylate, acetylated lanolin alcohol, EDTA, a foam stabilizer, 18 water, and inert polyethylene granules can be added without altering the effectiveness of 19 the treatment. 20 It is a yet further object of the present invention to provide a treatment that is safe 21 to use. INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 It is yet another object of the present invention to provide such treatment that is 2 topical, can be purchased over the counter, and is economical. 3 TV. SUMMARY OF THE INVENTION 4 The above objects of the invention are provided for in a topical treatment for acne 5 vulgaris. According to the invention, a method is provided for applying a composition of 6 substances to the infected area, working the composition into the infected area, and 7 removing the composition from the infected area. The composition comprises at least 8 one ethoxylate in combination with Sodium Lauroyl Sarcosinate (or "SLS"). An inert 9 scrubbing agent, such as polyethylene beads, can also be included to the formula. 10 Acetylated lanolin alcohol, a second ethoxylate, EDTA, a foam stabilizer, and water can 11 also be added to the composition without effecting performance. 12 Other formulas that keep the polarity similar to that of the inventive formula will 13 also work. To keep the polarity similar, it is necessary for the compound to have similar 14 characteristics, such as Carbon chains, carbonyl groups, Nitrogen bound to Carbon, 15 Aromatic ring(s), Oxylate groups, and appropriate functional groups at the ends of the 16 individual molecules. The ideal substitute chemicals would have all of the characteristics 17 mentioned above, but it is not necessary to have every one of those as listed. For 18 example, if the functional groups at the ends of the individual molecules are exchanged 19 for other functional groups that retain the ability to undergo an emulsion polymerization, 20 then the effectiveness of the compound is also retained. Another example is to change the 21 ethoxylate to a methoxylate or propoxylate. These formations would still retain a similar INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 polarity but would be different compounds with different characteristics. Yet another 2 example would be to exchange triply bound Nitrogen with a doubly bound or perhaps 3 Nitrogen with 4 Carbons bound to it. 4 V. DETAILED DESCRIPTION OF THE INVENTION 5 Chemical analysis and research has revealed that two of the component parts of 6 the inventive composition are principally involved in its effectiveness as an acne 7 treatment: an ethoxylate and Sodium Lauroyl Sarcosinate ("SLS"). The ethoxylate is 8 preferably a nonyl phenol ethoxylate. 9 The Inventor has also found, however, that other formulas that keep the polarity 10 similar to that of the inventive formula will also work. To keep the polarity similar, it is 11 necessary for the compound to have similar characteristics, such as Carbon chains, 12 carbonyl groups, Nitrogen bound to Carbon, Aromatic ring(s), Oxylate groups, and 13 appropriate functional groups at the ends of the individual molecules. The ideal 14 substitute chemicals would have all of the characteristics mentioned above, but it is not 15 necessary to have every one of those as listed. For example, if the functional groups at the 16 ends of the individual molecules are exchanged for other functional groups that retain the 17 ability to undergo an emulsion polymerization, then the effectiveness of the compound is 18 also retained. Another example is to change the ethoxylate to a methoxylate or 19 propoxylate. These formations would still retain a similar polarity but would be different 20 compounds with different characteristics. Yet another example would be to exchange INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 triply bound Nitrogen with a doubly bound or perhaps Nitrogen with 4 Carbons bound to 2 it. 3 The inventor has also discovered that the addition of an inert scrubbing agent 4 improves the action of the inventive composition. The beads should be large enough to 5 be effective but not so large as to cause abrasions. The inventor suggests beads in the 6 range of 5 to 50 microns with an average size being approximately 25 microns or 50 7 mesh. 8 To make the inventive composition, an exact ratio of ethoxylate to SLS is not 9 critical. The only requirement is that the ethoxylate is completely reacted with the SLS, 10 creating a polymer. This will vary with the ethoxylate used, but the Inventor has 11 determined that a ratio of ethoxylate-to- SLS of 1.5:2 is preferred. The amount by weight 12 of polyethylene beads can vary according to the grittiness desired. The Inventor has 13 found that a formula of ethoxylate: SLS .polyethylene of 40:20:40 is preferred but that 14 formulas of other concentrations are useful. Thus, for production purposes, formulas 15 having SLS ranging from 10 to 20 % by weight, ethoxylate ranging from 20 to 40 % by 16 weight, and polyethylene beads from 20 to 50% by weight are reasonable. But again, the 17 formula is not restricted to these ranges, which ranges are presented for example purposes 18 only. 19 Also, a cutting agent that does not chemically react with the composition may be 20 added. The cutting agent makes the overall composition flow more easily, thereby INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 enabling more packaging options, such as tubes. The cutting agent must be added only in 2 sufficient amount that it promotes flow but does not effect the action of the composition. 3 In use, an sufficient amount of the composition is used to cover the infected area, 4 the composition is applied to an infected area and worked over the area by a scrubbing 5 motion. After sufficient time has elapsed to ensure that the infected area has been 6 adequately exposed to the composition such that they area feels clean, approximately ten 7 to thirty seconds for the typical person, the area is rinsed cleaned.

Claims

INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 CLAIMS 2 I CLAIM: 3 1. A Treatment for Acne Vulgaris comprising sodium lauroyl sarcosinate and a 4 nonyl phenyl ethoxylate in combination. 5 6 2. The treatment for Acne Vulgaris of Claim 1 further including a second nonyl 7 phenyl ethoxylate. 8 9 3. The treatment for Acne Vulgaris of Claim 1 further including acetylated lanolin 10 alcohol. 11 12 4. The treatment for Acne Vulgaris of Claim 1 further including polyethylene 13 granules. 14 15 5. The treatment for Acne Vulgaris of Claim 1 further including water. 16 17 6. The treatment for Acne Vulgaris of Claim 1 further including 18 ethylenediaminetetraacetic acid. 19 20 7. The treatment for Acne Vulgaris of Claim 1 further including a foam stabilizing 21 agent. INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 2 8. The treatment for Acne Vulgaris of Claim 1 further including a cutting agent. 3 4 9. The cutting agent of Claim 8 being selected from the group of aqueous based 5 solutions and oil based solutions. 6 7 10. The treatment for Acne Vulgaris of Claim 1 wherein the ethoxylate is exchanged 8 for a methoxylate. 9 10 11. The treatment for Acne Vulgaris of Claim 1 wherein the ethoxylate is exchanged 11 for a propoxylate. 12 13 12. A treatment for Acne Vulgaris comprising an ethoxylate, sodium lauroyl 14 sarcosinate, and scrubbing means. 15 16 13. The treatment for Acne Vulgaris of Claim 12 wherein the scrubbing mean is 17 polyethylene beads. 18 19 14. The treatment for Acne Vulgaris of Claim 12 further including a cutting agent. 20 INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 15. The treatment for Acne Vulgaris of Claim 12 wherein the ethoxylate is exchanged 2 for a methoxylate. 3 4 16. The treatment for Acne Vulgaris of Claim 12 wherein the ethoxylate is exchanged 5 for a propoxylate. 6 7 17. A treatment for Acne Vulgaris comprising: a first ethoxylate, a second ethoxylate, 8 acetylated lanolin alcohol, sodium lauroyl sarcosinate, EDTA, a foam stabilizer, water, 9 and inert polyethylene granules. 10 11 18. The treatment for Acne Vulgaris of Claim 17 wherein the first ethoxylate is 12 exchanged for a methoxylate. 13 14 19. The treatment for Acne Vulgaris of Claim 17 wherein the first ethoxylate is 15 exchanged for a propoxylate. 16 17 20. A treatment for Acne Vulgaris comprising an ethoxylate, sodium lauroyl 18 sarcosinate, and EDTA. 19 20 21. The treatment for Acne Vulgaris of Claim 20 wherein the ethoxylate is exchanged 21 for a methoxylate. INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 2 22. The treatment for Acne Vulgaris of Claim 20 wherein the ethoxylate is exchanged 3 for a propoxylate. 4 5 23. A method for treating Acne Vulgaris comprising the steps of: 6 preparing a composition comprising an ethoxylate and sodium lauroyl 7 sarcosinate; 8 applying the composition to an infected area; 9 permitting the composition to remain on the infected area a sufficient 10 amount of time to enable the composition of matter to cause an effect; and, 11 removing the composition from the infected area. 12 13 24. The method of Claim 23 wherein preparing the composition further includes 14 adding second ethoxylate. 15 16 25. The method of Claim 23 wherein preparing the composition further includes 17 adding acetylated lanolin alcohol. 18 19 26. The method of Claim 23 wherein preparing the composition further includes 20 adding acetylated polyethylene granules. 21 INVENTION: Treatment for Acne Vulgaris Treatment and Method of Use
INVENTOR: William Yarbrough
1 27. The method of Claim 23 wherein preparing the composition further includes 2 adding water. 3 4 28. The method of Claim 23 wherein preparing the composition further includes 5 EDTA. 6 7 29. The method of Claim 23 wherein preparing the composition further includes a 8 foam stabilizer. 9 10 30. The method of Claim 23 further including the step of adding a thinning agent to 11 the composition. 12 13 31. The method of Claim 23 wherein the ethoxylate is exchanged for a methoxylate. 14 15 32. The method of Claim 23 wherein the ethoxylate is exchanged for a propoxylate.
PCT/US2003/025207 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use WO2005018629A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003264053A AU2003264053A1 (en) 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use
JP2005508238A JP2007521234A (en) 2003-08-12 2003-08-12 Therapeutic agent and method of use for acne vulgaris
PCT/US2003/025207 WO2005018629A1 (en) 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use
EP03818329A EP1656128A4 (en) 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use
CA002535550A CA2535550A1 (en) 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/025207 WO2005018629A1 (en) 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use

Publications (1)

Publication Number Publication Date
WO2005018629A1 true WO2005018629A1 (en) 2005-03-03

Family

ID=34215304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/025207 WO2005018629A1 (en) 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use

Country Status (5)

Country Link
EP (1) EP1656128A4 (en)
JP (1) JP2007521234A (en)
AU (1) AU2003264053A1 (en)
CA (1) CA2535550A1 (en)
WO (1) WO2005018629A1 (en)

Cited By (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009060083A2 (en) * 2007-11-08 2009-05-14 L'oreal Use of an n-acylated sarcosinate as an agent against microbial adhesion
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
WO2011003622A1 (en) 2009-07-10 2011-01-13 Ablynx N.V. Method for the production of variable domains
DE112009000507T5 (en) 2008-03-05 2011-02-10 Ablynx Nv Novel antigen-binding dimer complexes, process for their preparation and their use
WO2011026945A1 (en) 2009-09-03 2011-03-10 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
WO2011098520A1 (en) 2010-02-10 2011-08-18 Novartis Ag Agonist dr5 binding polypeptides
WO2011098552A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Methods and compositions for the preparation of aerosols
WO2011144749A1 (en) 2010-05-20 2011-11-24 Ablynx Nv Biological materials related to her3
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
WO2012056000A1 (en) 2010-10-29 2012-05-03 Ablynx Nv Method for the production of immunoglobulin single variable domains
WO2012062713A1 (en) 2010-11-08 2012-05-18 Novartis Ag Cxcr2 binding polypeptides
WO2012130872A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
WO2012152823A1 (en) 2011-05-09 2012-11-15 Ablynx Nv Method for the production of immunoglobulin single variable domains
WO2012156219A1 (en) 2011-05-05 2012-11-22 Ablynx Nv Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
WO2012163887A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
WO2012175740A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Immunoglobulin single variable domains directed against ige
EP2557090A2 (en) 2006-12-19 2013-02-13 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2650311A2 (en) 2007-11-27 2013-10-16 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
US8858940B2 (en) 2008-12-10 2014-10-14 Ablynx N.V. Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US9005963B2 (en) 2008-10-14 2015-04-14 Ablynx N.V. Amino acid sequences directed against cellular receptors for viruses and bacteria
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
EP2947097A1 (en) 2008-04-07 2015-11-25 Ablynx N.V. Amino acid sequences directed against the Notch pathways and uses thereof
WO2015193452A1 (en) 2014-06-18 2015-12-23 Ablynx Nv Kv1.3 binding immunoglobulins
EP2982690A1 (en) 2009-04-30 2016-02-10 Ablynx N.V. Method for the production of domain antibodies
WO2016097313A1 (en) 2014-12-19 2016-06-23 Ablynx N.V. Cysteine linked nanobody dimers
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US9562109B2 (en) 2010-11-05 2017-02-07 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP3205670A1 (en) 2009-06-05 2017-08-16 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2017200476A1 (en) 2016-05-19 2017-11-23 Biocool Ab New use of product for skin treatment
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2018050833A1 (en) 2016-09-15 2018-03-22 Ablynx Nv Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
US9949915B2 (en) 2016-06-10 2018-04-24 Clarity Cosmetics Inc. Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use
EP3311837A1 (en) 2011-09-23 2018-04-25 Ablynx NV Prolonged inhibition of interleukin-6 mediated signaling
WO2018091606A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
US9994639B2 (en) 2011-03-28 2018-06-12 Ablynx N.V. Biological materials related to CXCR7
EP3335724A1 (en) 2014-06-16 2018-06-20 Ablynx NV Immunoglobulin single variable domains for use in methods of treating ttp
WO2018158335A1 (en) 2017-02-28 2018-09-07 Vib Vzw Means and methods for oral protein delivery
WO2018206734A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
WO2018220235A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Mmp13 binding immunoglobulins
WO2018220225A1 (en) 2017-06-02 2018-12-06 Ablynx Nv Aggrecan binding immunoglobulins
WO2018220234A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Adamts binding immunoglobulins
WO2018220236A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Polypeptides binding adamts5, mmp13 and aggrecan
EP3424526A1 (en) 2008-06-05 2019-01-09 Ablynx NV Immunoglobulin single variable domains binding to the g envelope protein of rabies virus and uses thereof for the treatment and prevention of rabies
WO2019016237A1 (en) 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
EP3461844A2 (en) 2009-04-10 2019-04-03 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2019086548A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
WO2019154867A1 (en) 2018-02-06 2019-08-15 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
WO2019166622A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
WO2019180204A1 (en) 2018-03-23 2019-09-26 Université Libre de Bruxelles Wnt signaling agonist molecules
US10512739B2 (en) 2014-10-10 2019-12-24 Vectura Gmbh Inhalation device for use in aerosol therapy of respiratory diseases
US10561805B2 (en) 2014-10-10 2020-02-18 Ablynx N.V. Methods of treating RSV infections
WO2020185069A1 (en) 2019-03-08 2020-09-17 Linxis B.V. Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
WO2020239934A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
WO2021116252A1 (en) 2019-12-12 2021-06-17 Vib Vzw Glycosylated single chain immunoglobulin domains
WO2021213435A1 (en) 2020-04-22 2021-10-28 迈威(上海)生物科技股份有限公司 Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
EP3932945A1 (en) 2015-11-27 2022-01-05 Ablynx NV Polypeptides inhibiting cd40l
WO2022060223A1 (en) 2020-09-16 2022-03-24 Linxis B.V. Internalizing binding molecules
WO2022063947A1 (en) 2020-09-24 2022-03-31 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
WO2022120388A2 (en) 2020-12-04 2022-06-09 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2022178255A2 (en) 2021-02-19 2022-08-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that neutralize sars-cov-2
WO2022175392A1 (en) 2021-02-17 2022-08-25 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
WO2022242892A1 (en) 2021-05-17 2022-11-24 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2023281120A1 (en) 2021-07-09 2023-01-12 Luxembourg Institute Of Health (Lih) Dimeric protein complexes and uses thereof
EP4119662A1 (en) 2013-05-10 2023-01-18 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
WO2023240156A1 (en) 2022-06-08 2023-12-14 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024008274A1 (en) 2022-07-04 2024-01-11 Universiteit Antwerpen T regulatory cell modification
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539031A (en) * 1975-02-22 1979-01-24 Beecham Group Ltd Pharmaceutical compositions
WO2000003686A2 (en) * 1998-07-20 2000-01-27 Sarlo Peter V Acne treatment compositions
US6423746B1 (en) * 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147782A (en) * 1976-06-24 1979-04-03 William H. Rorer, Inc. Pharmaceutical detergent composition
US7008963B2 (en) * 1999-07-03 2006-03-07 The William M. Yarbrough Foundation Urushiol induced contact dermatitis solution

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539031A (en) * 1975-02-22 1979-01-24 Beecham Group Ltd Pharmaceutical compositions
WO2000003686A2 (en) * 1998-07-20 2000-01-27 Sarlo Peter V Acne treatment compositions
US6423746B1 (en) * 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1656128A4 *

Cited By (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2557090A2 (en) 2006-12-19 2013-02-13 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2009060083A2 (en) * 2007-11-08 2009-05-14 L'oreal Use of an n-acylated sarcosinate as an agent against microbial adhesion
FR2923383A1 (en) * 2007-11-08 2009-05-15 Oreal USE OF AN N-ACYLATED SARCOSINATE AS A MICROBIAL ANTI-ADHESION AGENT.
WO2009060083A3 (en) * 2007-11-08 2010-12-23 L'oreal Use of an n-acylated sarcosinate as an agent against microbial adhesion
EP2650311A2 (en) 2007-11-27 2013-10-16 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US9969805B2 (en) 2007-11-27 2018-05-15 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
DE112009000507T5 (en) 2008-03-05 2011-02-10 Ablynx Nv Novel antigen-binding dimer complexes, process for their preparation and their use
EP2947097A1 (en) 2008-04-07 2015-11-25 Ablynx N.V. Amino acid sequences directed against the Notch pathways and uses thereof
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
EP3424526A1 (en) 2008-06-05 2019-01-09 Ablynx NV Immunoglobulin single variable domains binding to the g envelope protein of rabies virus and uses thereof for the treatment and prevention of rabies
US9005963B2 (en) 2008-10-14 2015-04-14 Ablynx N.V. Amino acid sequences directed against cellular receptors for viruses and bacteria
US9803018B2 (en) 2008-10-14 2017-10-31 Ablynx N.V. Amino acid sequences directed against cellular receptors for viruses and bacteria
US9382333B2 (en) 2008-12-10 2016-07-05 Ablynx N.V. Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
US8858940B2 (en) 2008-12-10 2014-10-14 Ablynx N.V. Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
US9822175B2 (en) 2008-12-10 2017-11-21 Ablynx N.V. Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP3461844A2 (en) 2009-04-10 2019-04-03 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
EP2982690A1 (en) 2009-04-30 2016-02-10 Ablynx N.V. Method for the production of domain antibodies
EP3828201A1 (en) 2009-04-30 2021-06-02 Ablynx N.V. Method for the production of domain antibodies
EP3205670A1 (en) 2009-06-05 2017-08-16 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011003622A1 (en) 2009-07-10 2011-01-13 Ablynx N.V. Method for the production of variable domains
EP3438126A1 (en) 2009-09-03 2019-02-06 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2011026945A1 (en) 2009-09-03 2011-03-10 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2805731A2 (en) 2009-09-03 2014-11-26 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP3725330A1 (en) 2009-09-03 2020-10-21 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2011026948A1 (en) 2009-09-03 2011-03-10 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
EP3309176A1 (en) 2009-12-14 2018-04-18 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
WO2011098520A1 (en) 2010-02-10 2011-08-18 Novartis Ag Agonist dr5 binding polypeptides
WO2011098552A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Methods and compositions for the preparation of aerosols
EP3501499A1 (en) 2010-02-11 2019-06-26 Ablynx NV Methods and compositions for the preparation of aerosols
US9758584B2 (en) 2010-03-26 2017-09-12 Ablynx N.V. Biological materials related to CXCR7
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
WO2011144749A1 (en) 2010-05-20 2011-11-24 Ablynx Nv Biological materials related to her3
EP3546483A1 (en) 2010-05-20 2019-10-02 Ablynx N.V. Biological materials related to her3
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
WO2012056000A1 (en) 2010-10-29 2012-05-03 Ablynx Nv Method for the production of immunoglobulin single variable domains
EP3279214A1 (en) 2010-10-29 2018-02-07 Ablynx NV Method for the production of immunoglobulin single variable domains
US10875931B2 (en) 2010-11-05 2020-12-29 Zymeworks, Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US9562109B2 (en) 2010-11-05 2017-02-07 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP3578568A2 (en) 2010-11-08 2019-12-11 Ablynx N.V. Cxcr2 binding polypeptides
EP3575321A1 (en) 2010-11-08 2019-12-04 Ablynx N.V. Cxcr2 binding polypeptides
WO2012062713A1 (en) 2010-11-08 2012-05-18 Novartis Ag Cxcr2 binding polypeptides
US9994639B2 (en) 2011-03-28 2018-06-12 Ablynx N.V. Biological materials related to CXCR7
WO2012130872A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
EP4105231A1 (en) 2011-05-05 2022-12-21 Merck Patent GmbH Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
WO2012156219A1 (en) 2011-05-05 2012-11-22 Ablynx Nv Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
EP3363815A1 (en) 2011-05-05 2018-08-22 Merck Patent GmbH Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
EP3590950A1 (en) 2011-05-09 2020-01-08 Ablynx NV Method for the production of immunoglobulin single varible domains
WO2012152823A1 (en) 2011-05-09 2012-11-15 Ablynx Nv Method for the production of immunoglobulin single variable domains
WO2012163887A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
WO2012175740A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Immunoglobulin single variable domains directed against ige
EP3311837A1 (en) 2011-09-23 2018-04-25 Ablynx NV Prolonged inhibition of interleukin-6 mediated signaling
US9988460B2 (en) 2011-11-04 2018-06-05 Zymeworks Inc. Crystal structures of heterodimeric Fc domains
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US9732155B2 (en) 2011-11-04 2017-08-15 Zymeworks Inc. Crystal structures of heterodimeric Fc domains
US10457742B2 (en) 2011-11-04 2019-10-29 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US10508154B2 (en) 2012-06-25 2019-12-17 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US11078296B2 (en) 2012-11-28 2021-08-03 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
EP4119662A1 (en) 2013-05-10 2023-01-18 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
EP3335724A1 (en) 2014-06-16 2018-06-20 Ablynx NV Immunoglobulin single variable domains for use in methods of treating ttp
EP3366305A1 (en) 2014-06-16 2018-08-29 Ablynx NV Methods of treating ttp with immunoglobulin single variable domains and uses thereof
EP3335723A1 (en) 2014-06-16 2018-06-20 Ablynx NV Immunoglobulin single variable domains for use in methods of treating ttp
EP4059513A1 (en) 2014-06-16 2022-09-21 Ablynx NV Methods of treating ttp with immunoglobulin single variable domains and uses thereof
WO2015193452A1 (en) 2014-06-18 2015-12-23 Ablynx Nv Kv1.3 binding immunoglobulins
US10512739B2 (en) 2014-10-10 2019-12-24 Vectura Gmbh Inhalation device for use in aerosol therapy of respiratory diseases
US10561805B2 (en) 2014-10-10 2020-02-18 Ablynx N.V. Methods of treating RSV infections
WO2016097313A1 (en) 2014-12-19 2016-06-23 Ablynx N.V. Cysteine linked nanobody dimers
EP3932945A1 (en) 2015-11-27 2022-01-05 Ablynx NV Polypeptides inhibiting cd40l
WO2017200476A1 (en) 2016-05-19 2017-11-23 Biocool Ab New use of product for skin treatment
US10159637B2 (en) 2016-06-10 2018-12-25 Clarity Cosmetics Inc. Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use
US10813872B2 (en) 2016-06-10 2020-10-27 Clarity Cosmetics Inc. Hair and scalp formulations
US11160746B2 (en) 2016-06-10 2021-11-02 Clarity Cosmetics Inc. Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use
US9949915B2 (en) 2016-06-10 2018-04-24 Clarity Cosmetics Inc. Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
WO2018050833A1 (en) 2016-09-15 2018-03-22 Ablynx Nv Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
WO2018091606A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
WO2018158335A1 (en) 2017-02-28 2018-09-07 Vib Vzw Means and methods for oral protein delivery
WO2018206734A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
WO2018220236A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Polypeptides binding adamts5, mmp13 and aggrecan
EP4272822A2 (en) 2017-06-02 2023-11-08 Merck Patent GmbH Adamts binding immunoglobulins
WO2018220234A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Adamts binding immunoglobulins
WO2018220225A1 (en) 2017-06-02 2018-12-06 Ablynx Nv Aggrecan binding immunoglobulins
WO2018220235A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Mmp13 binding immunoglobulins
WO2019016237A1 (en) 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
WO2019086548A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
WO2019154867A1 (en) 2018-02-06 2019-08-15 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
WO2019166622A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
US11858960B2 (en) 2018-03-01 2024-01-02 Vrije Universiteit Brussel Human PD-L1-binding immunoglobulins
EP4163295A1 (en) 2018-03-23 2023-04-12 Université Libre de Bruxelles Wnt signaling agonist molecules
WO2019180204A1 (en) 2018-03-23 2019-09-26 Université Libre de Bruxelles Wnt signaling agonist molecules
WO2020185069A1 (en) 2019-03-08 2020-09-17 Linxis B.V. Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
EP4378485A2 (en) 2019-03-08 2024-06-05 LinXis B.V. Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
WO2020239934A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
WO2021116252A1 (en) 2019-12-12 2021-06-17 Vib Vzw Glycosylated single chain immunoglobulin domains
WO2021213435A1 (en) 2020-04-22 2021-10-28 迈威(上海)生物科技股份有限公司 Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2022060223A1 (en) 2020-09-16 2022-03-24 Linxis B.V. Internalizing binding molecules
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
WO2022063947A1 (en) 2020-09-24 2022-03-31 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022120388A2 (en) 2020-12-04 2022-06-09 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2022175392A1 (en) 2021-02-17 2022-08-25 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
WO2022178255A2 (en) 2021-02-19 2022-08-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that neutralize sars-cov-2
WO2022242892A1 (en) 2021-05-17 2022-11-24 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2023281120A1 (en) 2021-07-09 2023-01-12 Luxembourg Institute Of Health (Lih) Dimeric protein complexes and uses thereof
WO2023240156A1 (en) 2022-06-08 2023-12-14 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024008274A1 (en) 2022-07-04 2024-01-11 Universiteit Antwerpen T regulatory cell modification
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Also Published As

Publication number Publication date
CA2535550A1 (en) 2005-03-03
EP1656128A1 (en) 2006-05-17
JP2007521234A (en) 2007-08-02
EP1656128A4 (en) 2007-02-28
AU2003264053A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
EP1656128A1 (en) Treatment for acne vulgaris and method of use
US6423746B1 (en) Urushiol induced contact dermatitis and method of use
CA2256960C (en) High glycerin containing anti-microbial cleansers
US4395398A (en) Dental hemostatic composition
US9730870B2 (en) Sodium hypochlorite-based body wash compositions
JP3434435B2 (en) Hair cosmetic composition having dandruff inhibitory effect
US10561626B2 (en) Method for treating urushiol induced contact dermatitis
US20080075776A1 (en) Topical Pharmaceutical Compositions Containing An Antiacne Compound And Antibiotic Compound
CN108066164B (en) Transparent composite cleaning composition and preparation method thereof
JP2008533037A (en) Benzoyl peroxide composition and method of use
EP1933840B1 (en) Use of delmopinol in the treatment of acne
JP2007238607A (en) Chlorine remover
JP2001504153A (en) Germicidal soap bar
JP2668853B2 (en) Kitchen detergent
WO2000069403A1 (en) Alpha amino acid composition and method for the treatment of skin
JP2001079568A (en) Dechlorinating agent
WO2004052358A1 (en) Urushiol induced contact dermatitis treatment and method of use
CA1220426A (en) Method of treating acne vulgaris and composition containing carbamide peroxide
JP2007502289A (en) Compositions for the treatment of biting and invasive organisms, parasites and urticaria, and methods of use
EP1982694B1 (en) Anti-oedema composition
US20050037039A1 (en) Composition for treatment of tinea pedis and method of use
JP2000143440A (en) Bactericidal agent comprising string-shaped giant micelle
TH17177A (en) Topical formulation containing water
CN85106029A (en) A kind ofly can remove pigmented spots, freckle, promote the pure white cosmetics materials of skin
PL194902B1 (en) Method of obtaining a gel-type antiacneic preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AU BR CA CN CR HU IL IN JP KR MX NO NZ PH PL SC SG US ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2535550

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/001668

Country of ref document: MX

Ref document number: 2003818329

Country of ref document: EP

Ref document number: 2005508238

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003818329

Country of ref document: EP